Form 4: Halozyme Therapeutics SVP Exercises Options and Sells Shares Under 10b5-1 Plan

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, executed transactions involving the company's common stock.
• On April 16 and 17, 2024, LaBarre exercised options to purchase 10,000 shares of common stock on each day at a price of $8.11 per share.
• Simultaneously, LaBarre sold 10,000 shares on each day at $38.35 and $38.489 respectively.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2023.
• Following these transactions, LaBarre beneficially owns 168,176 shares of common stock.
• LaBarre also owns options to purchase 41,715 shares of common stock after the transactions on April 17, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy. It doesn't necessarily indicate a positive or negative outlook on the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the transactions are under a 10b5-1 plan, large sales by insiders could potentially create short-term negative sentiment.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are routine disclosures of insider transactions and are common in the pharmaceutical industry. Investors monitor these filings to understand management's perspective on the company's stock.

Comparison to Industry Standards

• Insider trading activity is common across publicly listed companies, including pharmaceutical firms like Halozyme.
• Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also see regular Form 4 filings from their executives.
• The use of 10b5-1 trading plans is a standard practice to allow insiders to sell shares without being accused of acting on non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential for short-term price fluctuations.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates